Clinical Trials

Clinical Trial Detail

Return to search results.

A Randomized, Double-Blind and Placebo-Controlled Study of GS-1101 in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)

Complete title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of GS-1101 (CAL-101) in Combination with Rituximab for Previously Treated Chronic Lymphocytic Leukemia

Research Study Number       2612.00
    
Principal Investigator       John Pagel, MD, PhD
    
Phase       III

Look up trial at NIH

Research Study Description

The purpose of this study is to evaluate the effect of GS-1101 on the onset, magnitude, and duration of tumor control.

Eligibility Criteria (must meet the following to participate in this study)

Ages Eligible for Study: 18 Years and older

Genders Eligible for Study: Both

- Adult subjects with previously treated recurrent CLL who have measurable lymphadenopathy

- Require therapy for CLL

- Have experienced CLL progression <24 months since the completion of the last prior therapy

- Currently not sufficiently fit to receive cytotoxic therapy because of chemotherapy-induced bone marrow damage or comorbidities.

Other eligibility criteria may apply.



Research Study Number       2612.00
    
Contact       Seattle Cancer Care Alliance Intake Office
    
Telephone       800-804-8824 / 206-288-1024
    
   

Keywords
Chronic Lymphoid Leukemia (CLL); Hematologic Malignancies; Leukemia

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials

Fred Hutchinson Cancer Research Center is a world leader in research to prevent, detect and treat cancer and other life-threatening diseases.